Search

Your search keyword '"Mertsoylu, Huseyin"' showing total 161 results
Start Over Author "Mertsoylu, Huseyin"
161 results on '"Mertsoylu, Huseyin"'

16. A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study)

Author

Abali, Huseyin, primary, Yalcin, Suayib, additional, Onal, Huseyin C., additional, Dane, Faysal, additional, Oksuzoglu, Berna, additional, Ozdemir, Nuriye, additional, Mertsoylu, Huseyin, additional, Artac, Mehmet, additional, Camci, Celaletdin, additional, Karabulut, Bulent, additional, Basal, Fatma B., additional, Budakoglu, Burcin, additional, Sendur, Mehmet A.N., additional, Goktas, Burce, additional, Ozdener, Fatih, additional, and Baygul, Arzu, additional

Published
2021
Full Text
View/download PDF

17. Prechemoradiotherapy Systemic Inflammation Response Index Stratifies Stage IIIB/C Non-Small-Cell Lung Cancer Patients into Three Prognostic Groups: A Propensity Score-Matching Analysis

Author

Topkan, Erkan, primary, Selek, Ugur, additional, Kucuk, Ahmet, additional, Haksoyler, Veysel, additional, Ozdemir, Yurday, additional, Sezen, Duygu, additional, Mertsoylu, Huseyin, additional, Besen, Ali Ayberk, additional, Bolukbasi, Yasemin, additional, Ozyilkan, Ozgur, additional, and Pehlivan, Berrin, additional

Published
2021
Full Text
View/download PDF

18. Low Prognostic Nutritional Index Predicts Poor Clinical Outcomes in Patients with Stage IIIB Non-small-cell Lung Carcinoma Undergoing Chemoradiotherapy

Author

Ozdemir, Yurday, Topkan, Erkan, Mertsoylu, Huseyin, Selek, Ugur, Selek, Uğur (ORCID 0000-0001-8087-3140 & YÖK ID 27211), Özdemir, Yurday, Topkan, Erkan, Mertsoylu, Hüseyin, and School of Medicine

Subjects
0301 basic medicine, medicine.medical_specialty, medicine.medical_treatment, Medicine, Oncology, survival results, Gastroenterology, chemoradiotherapy, 03 medical and health sciences, 0302 clinical medicine, Prognostic nutritional index, Non-small-cell lung carcinoma, Prognosis, Chemoradiotherapy, Survival results, Internal medicine, non-small -cell lung carcinoma, Carcinoma, medicine, Original Research, Univariate analysis, Chemotherapy, Receiver operating characteristic, business.industry, Area under the curve, prognostic nutritional index, medicine.disease, Confidence interval, Radiation therapy, 030104 developmental biology, Cancer Management and Research, 030220 oncology & carcinogenesis, prognosis, business
Abstract

Purpose: to investigate the prognostic utility of the prognostic nutritional index (PNI) in stage IIIB non-small-cell lung carcinoma (NSCLC) patients undergoing concurrent chemoradiotherapy (CRT). Methods: a total of 358 stage IIIB NSCLC patients who received a total dose of 60-66 Gy (2 Gy/fraction) radiotherapy and >= 1 cycle(s) of platinum-based chemotherapy were analyzed. The receiver operating curve analysis was utilized to identify the optimal PNI cut-off value demonstrating a significant connection with the overall survival (OS), locoregional progression-free survival (LRPFS), and progression-free survival (PFS). Results: at a median follow-up time of 22.5 months (range: 2.4-123.5), 30.2% and 14% of the patients were still alive and free of disease progression, respectively.The median OS, LRPFS, and PFS were 25.2 [95% confidence interval (CI): 36.3-46.6 months], 15.4 (95% CI: 26.6-35.3 months), and 10.7 (95% CI: 36.8-69.9 months), individually, for the whole study accomplice. The ROC analysis revealed an optimum rounded cut-off that associated meaningfully with each of the OS [area under the curve (AUC): 84.1%; sensitivity: 75.9%;72.4% specificity], LRPFS (AUC: 92.4%; sensitivity: 87.9%; 85.1% specificity), and PFS (AUC: 80.1%; sensitivity: 73.7%; 71.6% specificity) at a value of 40.5. Comparative analyses revealed that the patients presenting with PNI 40.5. In univariate analyses, lower T-stage (1-2 vs 3-4; P< 0.001), lower N-stage (N2 vs N3; P< 0.001), anemia status (absent vs present; P< 0.001), weight loss status (= 5%; P< 0.001), and PM group (40.5; P, NA

Published
2020

21. Low Advanced Lung Cancer Inflammation Index Predicts Poor Prognosis in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Definitive Concurrent Chemoradiotherapy

Author

Topkan, Erkan, primary, Ozdemir, Yurday, additional, Kucuk, Ahmet, additional, Guler, Ozan Cem, additional, Sezer, Ahmet, additional, Besen, Ali Ayberk, additional, Mertsoylu, Huseyin, additional, Senyurek, Sukran, additional, Kilic Durankus, Nulifer, additional, Bolukbasi, Yasemin, additional, Selek, Ugur, additional, and Pehlivan, Berrin, additional

Published
2020
Full Text
View/download PDF

22. Comparison of Involved Field Radiotherapy versus Elective Nodal Irradiation in Stage IIIB/C Non-Small-Cell Lung Carcinoma Patients Treated with Concurrent Chemoradiotherapy: A Propensity Score Matching Study

Author

Topkan, Erkan, primary, Ozdemir, Yurday, additional, Guler, Ozan Cem, additional, Kucuk, Ahmet, additional, Besen, Ali Ayberk, additional, Mertsoylu, Huseyin, additional, Sezen, Duygu, additional, Akdemir, Eyub Yasar, additional, Sezer, Ahmet, additional, Bolukbasi, Yasemin, additional, Pehlivan, Berrin, additional, and Selek, Ugur, additional

Published
2020
Full Text
View/download PDF

26. A Phase Ii Study Of The Combination Of Oxaliplatin, Capecitabine, And Trastuzumab And Chemo-radiotherapy In The Adjuvant Setting In Operated Patients With Her2+ Gastric Or Gastroesophageal Junction Cancer (Toxag Study), A Turkish Oncology Group Study

Author

Abali, Huseyin, primary, Yalcin, Suayib, additional, Onal, Huseyin Cem, additional, Dane, Faysal, additional, Oksuzoglu, Berna, additional, Ozdemir, Nuriye, additional, Mertsoylu, Huseyin, additional, Artac, Mehmet, additional, Camci, Celaletdin, additional, Karabulut, Bulent, additional, Basal, Fatma Bugdayci, additional, Budakoglu, Burcin, additional, Sendur, Mehmet Ali, additional, Goktaş, Burce, additional, Ozdener, Fatih, additional, and Baygul, Arzu, additional

Published
2020
Full Text
View/download PDF

28. Clinicohistopathological features and treatment outcomes of neuroendocrine tumors: a single center experience

Author

Sedef, Ali Murat, Kose, Fatih, Sumbul, Ahmet Taner, Mertsoylu, Huseyin, Besen, Ali Ayberk, Sezer, Ahmet, Ozyilkan, Ozgur, Abali, Huseyin, and Acibadem University Dspace

Subjects
Single center experience, Neuroendocrine tumors, Outcomes
Abstract

Purpose: Tumor and patient characteristics of neuroendocrine tumors (NET) significantly change between geographical locations that probably induced by environmental and genetic factors throughout the world. Therefore, reporting single center experience may help clarifying epidemiological view and improving decision-making process. Materials and Methods: We performed retrospective analysis of 115 patients of NETs those who followed by Baskent University, department of Medical Oncology and department of General Surgery to record patients and tumors characteristics, treatment modalities, survival rates, and prognostic factors. Results: Median overall survival (OS) time for all group and localized NETs were 44 and 24 months, respectively. Most common primary site was found as gastrointestinal system and then pancreatic region. Curative surgical resection rate was 46\% and 8.5\% of patients presented with carcinoid syndrome. Liver metastasis was far the most common metastatic site compared to lung, bone, and lymph node metastasis. Over 70 percent of patients were treated with chemotherapy and somatostatin analogs. Conclusion: Patients with higher grade, male gender, and advanced age (>65 years old) had poor survival rate. However, relatively low number of patients and less usage of (

Published
2018

32. The Hematologic Parameters in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate

Author

Onal, Cem, primary, Sedef, Ali Murat, additional, Kose, Fatih, additional, Oymak, Ezgi, additional, Guler, Ozan Cem, additional, Sumbul, Ahmet Taner, additional, Aksoy, Sercan, additional, Akkus Yildirim, Berna, additional, Besen, Ali Ayberk, additional, Muallaoglu, Sadık, additional, Mertsoylu, Huseyin, additional, and Ozyigit, Gokhan, additional

Published
2019
Full Text
View/download PDF

33. The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.

Author

Cem, Onal, primary, Sedef, Ali Murat, additional, KOse, Fatih, additional, Oymak, Ezgi, additional, Guler, Ozan Cem, additional, Sumbul, Ahmet Taner, additional, Aksoy, Sercan, additional, Akkus Yildrim, Berna, additional, Besen, Ali Ayberk, additional, Mullaoglu, Sadik, additional, Mertsoylu, Huseyin, additional, and Ozyigit, Gokhan, additional

Published
2019
Full Text
View/download PDF

34. The outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.

Author

Yildirim, Berna, primary, Cem, Onal, additional, KOse, Fatih, additional, Oymak, Ezgi, additional, Sedef, Ali Murat, additional, Besen, Ali Ayberk, additional, Aksoy, Sercan, additional, Guler, Ozan Cem, additional, Sumbul, Ahmet Taner, additional, Mertsoylu, Huseyin, additional, and Ozyigit, Gokhan, additional

Published
2019
Full Text
View/download PDF

36. Baseline Low Prognostic Nutritional Index Predicts Poor Survival in Locally Advanced Nasopharyngeal Carcinomas Treated With Radical Concurrent Chemoradiotherapy.

Author

Topkan, Erkan, Yucel Ekici, Nur, Ozdemir, Yurday, Besen, Ali Ayberk, Mertsoylu, Huseyin, Sezer, Ahmet, and Selek, Ugur

Subjects
CANCER patients, CANCER relapse, CISPLATIN, MULTIVARIATE analysis, NASOPHARYNX cancer, SURVIVAL, TREATMENT effectiveness, RETROSPECTIVE studies, RECEIVER operating characteristic curves, DESCRIPTIVE statistics, NUTRITIONAL status, CHEMORADIOTHERAPY, DISEASE risk factors
Abstract

Background: To retrospectively assess the impact of prognostic nutritional index (PNI) on survival outcomes of patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) treated with concurrent chemoradiotherapy (CCRT). Methods: This study incorporated 154 patients with LA-NPC who received exclusive cisplatinum-based CCRT. Receiver operating characteristic (ROC) curve analysis was utilized for accessibility of pretreatment PNI cutoffs influencing survival results. The primary end point was the interaction between the overall survival (OS) and PNI values, while cancer-specific survival (CSS) locoregional progression-free survival (LR-PFS), distant metastasis–free survival (DMFS), and PFS were the secondary end points. Results: A rounded PNI cutoff value of 51 was identified in ROC curve analyses to exhibit significant link with CSS, OS, DMFS, and PFS outcomes, but not LR-PFS. Patients grouping per PNI value (≥51 [N = 95] vs <51 [N = 49]) revealed that PNI < 51 group had significantly shorter median CSS (P <.001), OS (P <.001), DMFS (P <.001), and PFS (P <.001) times than the PNI ≥ 51 group, and the multivariate results confirmed the PNI < 51 as an independent predictor of poor outcomes for each end point (P <.05 for each). The unfavorable impact of the low PNI was also continued at 10-year time point with survival rates of 77.9% versus 42.4%, 73.6% versus 33.9%, 57.9% versus 27.1%, and 52.6% versus 23.7% for CSS, OS, DMFS, and PFS, respectively. Additionally, we found that PNI < 51 was significantly associated with higher rates of weight loss >5% over past 6 months (49.2% versus 11.6%; P =.002) compared to PNI < 51 group. Conclusion: Low pre-CCRT PNI levels were independently associated with significantly reduced CSS, OS, DMFS, and PFS outcomes in patients with LA-NPC treated with definitive CCRT. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

37. Febrile neutropenia due to H1N1 infection: Rare entity

Author

Besen, Ayberk A., Kose, Fatih, Mertsoylu, Huseyin, Disel, Umut, and Ozyılkan, Ozgur

Abstract

Febrile neutropenia is one of the most feared complications in actively treated patients in oncology clinics. The impact of H1N1 infection on the management of the febrile neutropenia in endemic areas, especially if the patient is presented with pulmonary symptoms, is not clear.

Published
2024
Full Text
View/download PDF

39. Prognostic Usefulness Of Advanced Lung Cancer Inflammation Index In Locally-Advanced Pancreatic Carcinoma Patients Treated With Radical Chemoradiotherapy.

Author

Topkan, Erkan, Mertsoylu, Huseyin, Ozdemir, Yurday, Sezer, Ahmet, Kucuk, Ahmet, Besen, Ali Ayberk, Ozyilkan, Ozgur, and Selek, Ugur

Subjects
LUNG cancer, PNEUMONIA, CHEMORADIOTHERAPY, RECEIVER operating characteristic curves, CARCINOMA
Abstract

Background/Aims: Previously advanced lung cancer inflammation index (ALI) has been demonstrated to have prognostic utility in the stratification of patients into distinctive survival groups, but the prognostic value of ALI has never been explored in the setting of locally advanced pancreatic carcinomas (LAPC) treated with concurrent chemoradiotherapy (CCRT). Hence, we aimed to investigate the prognostic value of pre-treatment ALI in LAPC patients who underwent radical CCRT. Methods: Present retrospective cohort analysis incorporated 141 LAPC patients who received radical CCRT. Accessibility of baseline ALI cutoff(s) impacting survival outcomes was sought by receiver operating characteristic (ROC) curve analysis. Interaction between the ALI and overall- (OS) and progression-free survival (PFS) comprised our primary and secondary endpoints, respectively. Results: At a median follow-up of 14.4 months (range: 3.2–74.2), the median PFS and OS were 7.5 (%95 CI: 5.9–9.1) and 14.6 months (%95 CI: 11.6–17.6), respectively. ROC curve analyses set the ideal ALI cutoff value at 25.3 (AUC: 75.6%; sensitivity: 72.7%; specificity: 70.3%) that exhibited significant associations with both the OS and PFS results. Patient stratification into two groups per ALI [≤25.3 (N=75) versus>25.3 (N=66)] showed that the ALI>25.3 group had significantly superior median OS (25.8 versus 11.4 months; P<0.001) and PFS (15.9 versus 6.0 months; P<0.001) durations than its ALI≤25.3 counterpart. Other factors exhibiting significantly better OS and PFS rates were N0 stage (versus N1; P<0.05 for each endpoint) and CA 19-9 ≤90 U/mL (versus >90 U/mL; P<0.05 for each endpoint), respectively. These three factors were additionally asserted to be independent indicators of longer OS (P<0.05 for each) and PFS (P<0.05 for each) in multivariate analyses. Conclusion: Results of this hypothesis-generating research proposed the pre-CCRT ALI as a novel robust associate of OS and PFS outcomes for LAPC patients undergoing CCRT. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

40. Ergebnisse der lokoregionalen Strahlentherapie bei metastatischen kastrationsresistenten und mit Abirateronacetat behandelten Prostakarzinompatienten.

Author

Yildirim, Berna Akkus, Onal, Cem, Kose, Fatih, Oymak, Ezgi, Sedef, Ali Murat, Besen, Ali Ayberk, Aksoy, Sercan, Guler, Ozan Cem, Sumbul, Ahmet Taner, Muallaoglu, Sadık, Mertsoylu, Huseyin, and Ozyigit, Gokhan

Subjects
THERAPEUTIC use of antineoplastic agents, PROSTATE tumors treatment, ADENOCARCINOMA, COMBINED modality therapy, COMPARATIVE studies, DRUG administration, LONGITUDINAL method, RESEARCH methodology, MEDICAL cooperation, PREDNISONE, PROGNOSIS, PROSTATE tumors, RADIATION doses, RADIOTHERAPY, RESEARCH, STATISTICAL sampling, TUMOR classification, PROSTATE-specific antigen, EVALUATION research, RANDOMIZED controlled trials, RETROSPECTIVE studies
Abstract

Copyright of Strahlentherapie und Onkologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2019
Full Text
View/download PDF

43. A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+ gastric or gastroesophageal junction cancer (TOXAG study).

Author

Abali, Huseyin, primary, Yalcin, Suayib, additional, Onal, Cem, additional, Dane, Faysal, additional, Oksuzoglu, Berna, additional, Ozdemir, Nuriye, additional, Mertsoylu, Huseyin, additional, Artac, Mehmet, additional, Camci, Celaletdin, additional, Karabulut, Bulent, additional, Basal, Fatma Bugdaycı, additional, Budakoglu, Burcin, additional, Sendur, Mehmet Ali Nahit, additional, Goktas, Burce, additional, Ozdener, Fatih, additional, and Baygul, Arzu, additional

Published
2018
Full Text
View/download PDF

46. A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+ gastric or gastro-esophageal junction cancer (TOXAG study).

Author

Abali, Huseyin, primary, Yalcin, Suayib, additional, Onal, Huseyin Cem, additional, Dane, Faysal, additional, Oksuzoglu, Berna, additional, Ozdemir, Nuriye, additional, Mertsoylu, Huseyin, additional, Artac, Mehmet, additional, Camci, Celalettin, additional, Karabulut, Bulent, additional, Bugdayci Basal, Fatma, additional, Budakoglu, Burcin, additional, Sendur, Mehmet Ali Nahit, additional, Goktas, Burce, additional, Ozdener, Fatih, additional, and Calisgan, Arzu, additional

Published
2016
Full Text
View/download PDF

49. Can primary tumor localization predict the which patient will have benefit from addition of taxanes to platin-5-FU based regimens in metastatic gastric cancer. Multi center retrospective analysis from Turkey, Society of Turkish Oncology Group study.

Author

Kose, Fatih, primary, Sedef, Ali Murat, additional, Özdemir, Nuriye, additional, Gunaldi, Meral, additional, Urun, Yuksel, additional, Besen, Ali Ayberk, additional, Sumbul, Ahmet Taner, additional, Goksu, Sema Sezgin, additional, Dogan, Ozlem, additional, Mertsoylu, Huseyin, additional, Tatli, Ali Murat, additional, Erdem, Dilek, additional, Demirci, Serkan, additional, Gunduz, Seyda, additional, Yildirim, Mustafa, additional, Ozyilkan, Ozgur, additional, and Abali, Huseyin, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results